AbbVie

AbbVie jumps into STING cancer work with Mavupharma buy
AbbVie jumps into STING cancer work with Mavupharma buy
Fierce Biotech
AbbVie
Mavupharma
M&A
STING
immuno-oncology
Flag link:
NICE recommends funding for psoriasis and type 1 diabetes drugs
NICE recommends funding for psoriasis and type 1 diabetes drugs
Pharmaforum
NICE
UK
NHS
AbbVie
Skyrizi
AstraZeneca
Farxiga
Flag link:
Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
Fierce Pharma
AbbVie
Humira
Gilead Sciences
Biktarvy
Truvada
Pfizer
Xeljanz
television ads
DTC ads
Flag link:
Why AbbVie's Stock Sank in the First Half of 2019
Why AbbVie's Stock Sank in the First Half of 2019
Motley Fool
AbbVie
Humira
biosimilars
M&A
Allergan
Flag link:
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Endpoints
Gilead Sciences
AbbVie
FDA
JAK inhibitors
filgotinib
Upadacitinib
rheumatoid arthritis
Flag link:
Are AbbVie and Allergan Really Better Together?
Are AbbVie and Allergan Really Better Together?
Motley Fool
AbbVie
Allergan
M&A
Flag link:
AbbVie deal for Allergan not about the taxes thanks to 2017 law
AbbVie deal for Allergan not about the taxes thanks to 2017 law
Biopharma Dive
Allergan
AbbVie
M&A
taxes
Flag link:
5 reasons AbbVie bought Allergan, and why they may not be enough
5 reasons AbbVie bought Allergan, and why they may not be enough
Biopharma Dive
AbbVie
Allergan
M&A
Humira
Botox
cash
diversification
Flag link:
Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch
Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch
Endpoints
AbbVie
Allergan
M&A
R&D
layoffs
Flag link:
Here's Why Nobody's Happy About This $63 Billion Buyout
Here's Why Nobody's Happy About This $63 Billion Buyout
Motley Fool
AbbVie
Allergan
M&A
Flag link:
How Brent Saunders’ Allergan experiment failed
How Brent Saunders’ Allergan experiment failed
Stat
Brent Saunders
Allergan
AbbVie
Pharma CEOs
Flag link:
AbbVie’s $63 Billion Mistake
AbbVie’s $63 Billion Mistake
Motley Fool
AbbVie
Allergan
M&A
Flag link:
FDA lifts hold on AbbVie multiple myeloma study
FDA lifts hold on AbbVie multiple myeloma study
Biopharma Dive
FDA
AbbVie
Venclexta
clinical trials
Multiple Myeloma
Flag link:
AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants
AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants
Stat
AbbVie
Allergan
M&A
Humira
Flag link:
AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud
AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud
Endpoints
AbbVie
Venclexta
Multiple Myeloma
FDA
clinical trials
Flag link:
3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
Abbvie proves the best at getting the most out of its workers
Abbvie proves the best at getting the most out of its workers
EP Vantage
AbbVie
Bristol-Myers Squibb
Sanofi
AstraZeneca
revenue per employee
Flag link:
Meet the Top Ten Drugs of 2024 (Maybe)
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
AbbVie
Humira
Merck
Keytruda
Eliquis
Bristol-Myers Squibb
Imbruvica
Opdivo
Revlimid
Celgene
Flag link:
Lilly’s Taltz scrapes win against Humira in psoriatic arthritis
Lilly’s Taltz scrapes win against Humira in psoriatic arthritis
Pharmaforum
Eli Lilly
Taltz
AbbVie
Humira
psoriatic arthritis
Flag link:
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Flag link:

Pages